Recombinant EGFR (Nimotuzumab Biosimilar) anticorps

N° du produit ABIN7795094

Cet anticorps Humanized Monoclonal détecte spécifiquement EGFR (Nimotuzumab Biosimilar) dans FACS et in vivo. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Recombinant EGFR (Nimotuzumab Biosimilar) anticorps (ABIN7795094)

Antigène: EGFR (Nimotuzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR (Nimotuzumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-EGFR (Nimotuzumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Nimotuzumab Biosimilar, EGFR Monoclonal Antibody

Attributs du produit: Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab. Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division. It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain. Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human EGFR / ErbB-1

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur EGFR (Nimotuzumab Biosimilar)

Antigène: EGFR (Nimotuzumab Biosimilar)

Autre désignation: Nimotuzumab Biosimilar

Classe de substances: Biosimilar